Pharmaron Closes $40M Series C
Pharmaron Holding Limited has closed a $40 million Series C round. Existing investors DCM and Legend Capital joined new investor GL Capital Group in the round, which will be used to expand the company’s drug discovery services, toxicology capabilities and chemical synthesis services. Pharmaron was formed in 2003, and provides research and development services to the biotech and pharmaceutical industries.
24 February 2011•3 mins read
